Flora Growth Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Flora Growth in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Flora Growth stock.
View analyst ratings for Flora Growth or view top-rated stocks.

Wall Street analysts have given Flora Growth a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Flora Growth wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Flora Growth saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 753,100 shares, a drop of 22.6% from the August 15th total of 972,500 shares. Based on an average trading volume of 4,260,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 2.3% of the company's stock are short sold.
View Flora Growth's Short Interest.

1 equities research analysts have issued 12-month target prices for Flora Growth's shares. Their forecasts range from $11.50 to $11.50. On average, they expect Flora Growth's share price to reach $11.50 in the next year. This suggests a possible upside of 94.6% from the stock's current price.
View analysts' price targets for Flora Growth or view top-rated stocks among Wall Street analysts.

Some companies that are related to Flora Growth include Omeros (OMER), Rani Therapeutics (RANI), Prometheus Biosciences (RXDX), Merus (MRUS), ORIC Pharmaceuticals (ORIC), Syndax Pharmaceuticals (SNDX), BELLUS Health (BLUSF), Praxis Precision Medicines (PRAX), Crinetics Pharmaceuticals (CRNX), Vanda Pharmaceuticals (VNDA), Gracell Biotechnologies (GRCL), Design Therapeutics (DSGN), Stoke Therapeutics (STOK), BeyondSpring (BYSI) and Phibro Animal Health (PAHC).
View all of FLGC's competitors.

(FLGC) raised $15 million in an initial public offering on Tuesday, May 11th 2021. The company issued 3,300,000 shares at a price of $4.00-$5.00 per share. Boustead Securities acted as the underwriter for the IPO.

Flora Growth trades on the NASDAQ under the ticker symbol "FLGC."

Flora Growth's lock-up period expires on Monday, November 8th. Flora Growth had issued 3,333,333 shares in its public offering on May 11th. The total size of the offering was $16,666,665 based on an initial share price of $5.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Flora Growth's stock is owned by many different institutional and retail investors. Top institutional investors include Cobblestone Capital Advisors LLC NY (0.11%), Geode Capital Management LLC (0.04%), 360 Financial Inc. (0.03%), Morgan Stanley (0.02%) and Morgan Stanley (0.02%).

FLGC stock was acquired by a variety of institutional investors in the last quarter, including Cobblestone Capital Advisors LLC NY, Geode Capital Management LLC, 360 Financial Inc., Morgan Stanley, and Morgan Stanley.

Shares of FLGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLGC stock can currently be purchased for approximately $5.91.

Flora Growth has a market capitalization of $248.36 million and generates $110,000.00 in revenue each year.

The official website for Flora Growth is floragrowth.ca.

The company can be reached via phone at 416-861-2267.